标题：消癌平片联合常规化疗对胃癌患者血清TGF-α、VEGF水平的影响

      作者：王惠枫 1，沈静 2，张甜甜 1    上海市松江区方塔中医医院药剂科 1、肿瘤科 2，上海 201600

      卷次： 2020年31卷2期

      【摘要】 目的 探讨消癌平片联合常规化疗治疗胃癌的临床效果及其对患者转化生长因子-α (TGF-α)、血管内皮生长因子(VEGF)水平的影响。方法 选取2017年8月至2019年4月期间上海市松江区方塔中医医院接诊的82例胃癌患者作为研究对象，按随机数表法分为对照组和观察组，每组41例。对照组患者给予奥沙利铂联替吉奥胶囊化疗治疗，观察组在对照组治疗的基础上联合消癌平片治疗，21 d为1个疗程，3个疗程后评估治疗效果，比较两组患者的近期疗效、TGF-α、VEGF、视觉模拟疼痛(VAS)评分和毒副反应发生情况。结果 观察组患者3个疗程后总有效率为73.17%，明显高于对照组的51.22%，差异具有统计学意义(P<0.05)；3个疗程后观察组和对照组患者的TGF-α水平[(8.45±1.28) μg/L vs (13.29±2.05) μg/L]、VEGF水平[(148.51±19.25) pg/mL vs (242.59±20.59) pg/mL]及VAS评分[(1.14±0.31)分 vs (3.52±0.53)分]比较，观察组明显低于对照组，差异均具有统计学意义(P<0.05)；治疗过程中两组患者的骨髓抑制、肝肾损害、便秘腹泻、恶心呕吐及中性粒细胞异常发生率比较，差异均无统计学意义(P>0.05)。结论 消癌平片用于胃癌的治疗能降低患者的TGF-α、VEGF水平，减轻疼痛，且未增加毒副反应发生率，近期疗效显著，值得临床推广应用。
      【关键词】 消癌平片；胃癌患者；临床效果；转化生长因子-α；血管内皮生长因子；近期疗效
      【中图分类号】 R735.2 【文献标识码】 A 【文章编号】 1003—6350（2020）02—0181—03

Effect of Xiaoaiping tablet combined with conventional chemotherapy on serum TGF-α and VEGF content inpatients with gastric cancer.
WANG Hui-feng 1, SHEN Jing 2, ZHANG Tian-tian 1. Department of Pharmacy 1, OncologyDepartment of Oncology 2, the Fangta Traditional Chinese Medicine Hospital of Shanghai Songjiang District, Shanghai201600, CHINA
【Abstract】 Objective To investigate the clinical effect of Xiaoaiping tablet combined with conventional che-motherapy in the treatment of gastric cancer and its effect on the levels of transforming growth factor-α (TGF-α) andvascular endothelial growth factor (VEGF) in patients. Methods Eighty-two gastric cancer patients, who admitted tothe Fangta Traditional Chinese Medicine Hospital of Shanghai Songjiang District from August 2017 to April 2019, wereselected and divided into the control group and observation group according to random number table method, with 41 pa-tients in each group. The control group was treated with oxaliplatin combined with gimeracil and oteracil potassium cap-sules, and the observation group received the treatment of Xiaocanping tablets on the basis of the treatment in the controlgroup. The course of treatment was 21 d, and the treatment effect was evaluated after 3 courses of treatment. Theshort-term efficacy, TGF-α, VEGF, Visual Analogue Scale (VAS) score, and occurrence of toxic side effects of the twogroups were compared. Results The total effective rate of patients in the observation group after 3 courses was73.17%, which was significantly higher than 51.22% in the control group (P<0.05); the levels of TGF-α, VEGF, VASscores in the patients of the observation group after 3 courses were (8.45±1.28) μg/L, (148.51±19.25) pg/mL, (1.14±0.31) points, respectively, which were significantly lower than corresponding (13.29±2.05) μg/L, (242.59±20.59) pg/mL,(3.52±0.53) points in the control group (all P<0.05); there was no significant difference in the incidence rates of bonemarrow suppression, liver and kidney damage, constipation, diarrhea, nausea and vomiting, and neutrophil abnormalitiesbetween the two groups (P>0.05). Conclusion Xiaoaiping tablets can reduce the levels of TGF-α and VEGF and alle-viate pain in patients with gastric cancer. The drug does not increase the incidence of toxic and side effects, and has sig-nificant short-term effects, which is worthy of clinical promotion and application.
      【Key words】 Xiaoaiping tablets; Gastric cancer patients; Clinical effects; Transforming growth factor-α(TGF-α); Vascular endothelial growth factor (VEGF); Short-term efficacy